Management of Side Effects for Patients Receiving Multimodality Therapy in Thoracic Oncology
Presented by Marianne Davies, DNP, RN, CNS, ACNP, AOCNP®, and Beth Eaby-Sandy, MSN, CRNP
Yale University School of Nursing and Medicine and Yale Comprehensive Cancer Center, New Haven, Connecticut; and Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2019;10(3):245–251 |
© 2019 Harborside™
Advanced practitioners play an important role in recognizing and treating adverse events caused by multimodality therapies in lung cancer. Marianne Davies, DNP, RN, CNS, ACNP, AOCNP®, and Beth Eaby-Sandy, MSN, CRNP, detailed strategies for managing toxicities associated with EGFR, ALK/ROS1, and BRAF inhibitors.
For access to the full length article, please sign in